These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22407753)

  • 21. Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study.
    Zer A; Rizel S; Braunstein R; Yerushalmi R; Hendler D; Neimann V; Cioreuru N; Sulkes A; Stemmer SM
    Chemotherapy; 2012; 58(2):95-101. PubMed ID: 22377846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
    Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-resolution melting-based quantitative analysis of RASSF1 methylation in breast cancer.
    Stuopelytė K; Daniūnaitė K; Laurinavičienė A; Ostapenko V; Jarmalaitė S
    Medicina (Kaunas); 2013; 49(2):78-83. PubMed ID: 23888343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
    Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
    Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
    Ju NR; Jeffe DB; Keune J; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
    Korde LA; Lusa L; McShane L; Lebowitz PF; Lukes L; Camphausen K; Parker JS; Swain SM; Hunter K; Zujewski JA
    Breast Cancer Res Treat; 2010 Feb; 119(3):685-99. PubMed ID: 20012355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
    Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
    Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
    Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
    J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
    Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
    Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial.
    Fei F; Messina C; Slaets L; Chakiba C; Cameron D; Bogaerts J; Bonnefoi H
    Eur J Cancer; 2015 Feb; 51(3):301-9. PubMed ID: 25578377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascularity change and tumor response to neoadjuvant chemotherapy for advanced breast cancer.
    Kuo WH; Chen CN; Hsieh FJ; Shyu MK; Chang LY; Lee PH; Liu LY; Cheng CH; Wang J; Chang KJ
    Ultrasound Med Biol; 2008 Jun; 34(6):857-66. PubMed ID: 18374468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Factors related with pathological complete response of neoadjuvant chemotherapy in primary breast cancer].
    Cheng YJ; Ye JM; Xu L; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Apr; 51(4):339-43. PubMed ID: 23895756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.